Global Strategic Account Manager, Seer

$140-160k

This position is also eligible for bonus, benefits, and participation in Company’s equity plan

Senior level
Remote in EU, UK, US

More information about location

Seer

Empowering the scientific community through the power of proteomics

Open for applications

Seer

Empowering the scientific community through the power of proteomics

101-200 employees

B2BEnterpriseScienceBiotechnology

Open for applications

$140-160k

This position is also eligible for bonus, benefits, and participation in Company’s equity plan

Senior level
Remote in EU, UK, US

More information about location

101-200 employees

B2BEnterpriseScienceBiotechnology

Company mission

To decode the secrets of the proteome to improve human health.

Company mission

To decode the secrets of the proteome to improve human health.

Few candidates hear
back within 2 weeks

19% employee growth in 12 months

Our take

Seer offers tools and solutions that provide unbiased, deep, rapid and large-scale proteomics in the field of biotechnology. More specifically, Seer's life sciences and health data platform helps detect life-threatening diseases before symptoms start to show. The company claims to be able to analyze protein composition in a comparable way to sequencing machines ‘reading’ strands of DNA.

Seer has grown rapidly: the company went public in 2020 after being founded in 2017, and enjoys strong financial backing that has helped it launch a varied range of proteomics products.

Seer faces competition from the likes of Nautilus and Illumina, a multibillion giant in the sequencing world, who have a sub-division dedicated to proteomics. However, Seer has featured on the Deloittes Fast500 2023 and won multiple awards for its innovative product, putting it in good stead to grow rapidly.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Benefits

  • E-Verify Participation Notice
  • Family and Medical Leave Act
  • Pay Transparency Nondiscrimination Provision
  • Anti-Discrimination Notice/Right to Work

Funding (last 2 of 5 rounds)

Jul 2020

$55m

SERIES D

Dec 2019

$55m

SERIES D

Total funding: $169.5m

Leadership

Omid Farokhzad

(Chair and CEO)

Extensive experience as Chair, Director and Co-founder across multiple companies and technology platforms. Also a graduate of Harvard Medical School.

Jobs (3)

All locations

Marketing

Finance, Legal & Compliance

Sales & Account Management